3//SEC Filing
DCVC Bio, L.P. 3
Accession 0001209191-20-063107
CIK 0001703057other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 9:24 PM ET
Size
16.0 KB
Accession
0001209191-20-063107
Insider Transaction Report
Form 3
DCVC Bio, L.P.
10% Owner
Holdings
- (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying) - (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying) - (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying)
DCVC Bio GP, LLC
10% Owner
Holdings
- (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying) - (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying) - (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying)
ZNM Capital Management, LLC
10% Owner
Holdings
- (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying) - (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying) - (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying)
Ocko Matthew
10% Owner
Holdings
- (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying) - (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying) - (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying)
Stead Kiersten
10% Owner
Holdings
- (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying) - (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying) - (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying)
Bogue Zachary
10% Owner
Holdings
- (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying) - (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying) - (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying)
Footnotes (4)
- [F1]The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") are convertible into Common Shares at a 1:10 ratio into the number of Common Shares as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Preferred Shares have no expiration date.
- [F2]These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.
- [F3](Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.
- [F4]The convertible promissory note ("Convertible Note") has a maturity date of October 30, 2025 and the principal amount of the Convertible Note will convert upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.
Documents
Issuer
AbCellera Biologics Inc.
CIK 0001703057
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001735069
Filing Metadata
- Form type
- 3
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 9:24 PM ET
- Size
- 16.0 KB